NEW YORK / RankWire.AI / – On Wednesday, U.S. equities experienced modest advances, driven by a significant drop in long-term Treasury yields. The S&P 500 increased by 16.22 points, or 0.21%, reaching 7,707.98 and ending a streak of three consecutive losing sessions. The Dow Jones Industrial Average also advanced, climbing 119.65 points, or 0.22%, to close at 53,463.05. The Nasdaq Composite rose by 41.38 points, or 0.16%, to finish at 26,331.09. The decline in government bond yields played a role in helping the major indexes recover after multiple sessions marked by pressure from rising borrowing costs.

Bond prices increased following the U.S. Treasury Department’s announcement of expanded liquidity support through larger buybacks of longer-term government debt. Starting September 9, the cap on purchases will rise from $2 billion to a minimum of $4 billion per operation. This adjustment applies to nominal coupon securities within the 10-to-20-year and 20-to-30-year maturity brackets. The larger buyback limits will stay in effect until November 4. The department cited robust volumes of high-quality offers as the basis for increasing liquidity operations in these sectors.
Following the announcement, Treasury yields declined, reversing some of the recent upward trend in long-term borrowing costs. The 10-year Treasury yield dropped to approximately 4.65%, while the 30-year yield decreased to about 5.20%. Notably, the 30-year yield had reached 5.337% on Tuesday, its highest point since 2007. Since bond prices move inversely to yields, the improved demand for government debt pushed yields lower, alleviating some of the pressure that had resulted from the recent selloff in long-term bonds.
Healthcare Sector Bolsters Market Performance
The healthcare industry contributed further support during Wednesday’s trading session, with several pharmaceutical companies posting sizable gains. Moderna shares skyrocketed by 177%, and Merck rose by 12.6% after both companies reported positive outcomes from a Phase 3 melanoma trial. The INTerpath-001 study evaluated personalized mRNA therapy intismeran autogene combined with Keytruda after surgical removal of high-risk melanoma. The trial’s primary endpoint for recurrence-free survival was achieved, along with a key secondary measure of survival without distant cancer spread.
This rally in healthcare stocks helped balance out mixed trading elsewhere, especially within the technology sector. Consumer stocks also experienced gains following quarterly results from major companies. Estée Lauder jumped over 16% after its earnings release, boosting overall consumer stock performance. Similarly, Target and Lowe’s advanced after reporting their latest financial results. Smaller-cap stocks outperformed their larger counterparts, with the Russell 2000 index gaining roughly 0.5% as broader markets rebounded.
Major Indices End Three-Day Losing Streak
The rally on Wednesday marked the end of a three-day decline for the S&P 500, Dow, and Nasdaq. The rebound followed earlier week pressures from rising long-term yields that had weighed on equities. Despite Wednesday’s gains, the main indexes still finished the week lower. The S&P 500 was roughly 1% below its previous Friday’s level, while the Dow decreased by about 0.5%. The Nasdaq remained approximately 1.5% lower for the week.
Looking at the broader year-to-date performance, the indexes remained in positive territory despite the recent dip and bond market volatility. As of Wednesday’s close, the S&P 500 has risen around 12.6% since the start of the year. The Dow is up about 11.2%, and the Nasdaq leads with a roughly 13.3% increase, reflecting its stronger start to the year. Wednesday’s session thus represented a modest recovery for Wall Street, driven by falling Treasury yields and healthcare sector gains that supported all three major U.S. stock indexes.
